Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$4.59
Change (%) Stock is Up 0.15 (3.38%)
Volume143,227
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
05/15/19ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference
LOS ANGELES, May 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with institutional investors throughout ... 
Printer Friendly Version
05/09/19ChromaDex Corporation Reports First Quarter 2019 Financial Results
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased marketing efficiency Continued progress building TRU NIAGEN into a global brand with top-line momentum TRU NIAGEN net sales were $7.5 million, a 15% increase sequentially and a 146% increase year-over-year Global expansion continued with e-Commerce roll-out in Canada... 
Printer Friendly Version
05/09/19ChromaDex Announces $10 Million Issuance of Convertible Notes
Private Placement Led by High Profile Venture Capitalists and Strategic Investors LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The conver... 
Printer Friendly Version
What's New
DateTitle
05/22/19
May 2019 Investor Presentation PDF
05/09/19
Q1 2019 Earnings Presentation PDF
05/09/19
10-Q Quarterly report which provides a continuing view of a company's financial position Excel Adobe PDF Word XBRL
04/23/19
2019 Proxy Statement PDF
04/08/19
ChromaDex Investor FAQs Fourth Quarter 2018 PDF
03/11/19
March 2019 Investor Presentation PDF
03/07/19
Q4 2018 Earnings Presentation  PDF
03/07/19
2018 Annual Report on Form 10K  PDF
12/05/18
December 2018 Investor Presentation PDF
12/04/18
ChromaDex Investor FAQs Third Quarter 2018 PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.